# US 2002/0001615 A1 · Combined interferon alfa and lipsosmal-encapsulated all-trans retinoic acid, including preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001615 A1
- Document ID: US20020001615A1
- Status: Published application
- Kind: A1
- Application number: 09/811,346
- Filed: 2001-03-16
- Published: 2002-01-03
- Earliest claimed: 2000-03-31
- Assignees: Aronex Pharmaceuticals, Inc.
- Inventors: David Nanus
- Web page: https://patentgrep.com/patent/US20020001615A1

## CPC

- A61K 38/21: Interferons {[IFN]}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Alfa interferon (α-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of α-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from about 15 mg/m2 to about 90 mg/m2, or about 140 mg/m2, or about 300 mg/m2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.

## Claims

### Claim 1

A method of inhibiting the growth of cancer cells comprising exposing cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein said retinoid is associated with lipid carrier particles.

### Claim 2 (depends on 1)

The method of claim 1 wherein the retinoid is retinoic acid.

### Claim 3 (depends on 2)

The method of claim 2 wherein the retinoic acid is all-trans retinoic acid.

### Claim 4 (depends on 3)

The method of claim 3 wherein lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride and the molar ratio of retinoid to lipid is at least about 15:85, where the triglyceride is at least about 15% by weight of the composition, and where the composition is stable in an aqueous environment.

### Claim 5 (depends on 1)

The method of claim 1 comprising administering said retinoid composition in doses administered over a period of at least one-half hour.

### Claim 6 (depends on 1)

The method of claim 1 comprising administering said retinoid composition at a frequency of about every other day or less frequent.

### Claim 8 (depends on 1)

The method of claim 1 wherein the cancer is a renal cancer.

### Claim 9

A method of inhibiting the growth of cancer cells comprising
exposing cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and further
co-timely exposing of said cancerous cells to a therapeutically effective amount of a retinoid, wherein said retinoid is associated with lipid carrier particles.

### Claim 10

A therapeutic treatment kit for the treatment of cancer comprising interferon, retinoid and instructional materials for the combined use of said retinoid and interferon.
